Aurora kinase A (AURKA) belongs to the family of serine/threonine kinases, whose
activation is necessary for cell division processes via regulation of mitosis. AURKA shows …

Bcr-Abl inhibitors paved the way of targeted therapy epoch. Imatinib was the first tyrosine
kinase inhibitor to be discovered with high specificity for Bcr-Abl protein resulting from t (9 …

The microtubule-associated protein tau is integral to the pathogenesis of Alzheimer's
disease (AD), as well as several related disorders, termed tauopathies, in which tau is …

The Aurora kinase family is comprised of three serine/threonine kinases, Aurora‐A, Aurora‐
B, and Aurora‐C. Among these, Aurora‐A and Aurora‐B play central roles in mitosis …

Kinase inhibitors are the largest class of new cancer drugs. However, it is already apparent
that most tumours can escape from the inhibition of any single kinase. If it is necessary to …

The BCR-ABL1 fusion gene is a driver oncogene in chronic myeloid leukaemia and 30–50%
of cases of adult acute lymphoblastic leukaemia. Introduction of ABL1 kinase inhibitors (for …

In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the
T315I gatekeeper mutant has emerged as resistant to all currently approved agents. This …

Aurora kinase belongs to serine/threonine kinase family which controls cell division.
Therapeutic inhibition of Aurora kinase showed great promise as probable anticancer …

NEDD8 activating enzyme (NAE) has been identified as an essential regulator of the
NEDD8 conjugation pathway, which controls the degradation of many proteins with …

Standard therapeutic approaches of cytotoxics and radiation in cancer are not only highly
toxic, but also of limited efficacy in treatment of a significant number of cancer patients. The …